Urinary pathogen
Escherichia coli (UPEC) are the first cause of community-acquired and responsible for 50% of hospital-acquired urinary tract infections (UTIs) (
1,
2). UPEC strains act as opportunistic intracellular pathogens that colonize the urinary tract following predisposing factor including kidney stone, impaired immune function, kidney injury, history of urinary tract surgery, pregnancy, tumor, congenital malformation, diabetes, urinary retention, tuberculosis, or urinary tract manipulations such as catheterization (
3). UTIs are the predominant type of bacterial infection diagnosed nowadays. In fact,
E. coli are responsible for more than 85% of all UTIs controlled using antibiotic therapy all over the word.
Antibiotics are considered as the first-line treatment for bacterial infections that excessive and inappropriate use of them result in antibiotic resistance, which is now a rapidly growing global problem (
4,
5).
E. coli is one of the opportunistic pathogens in hospitals, especially in inpatients (
6). In addition to UTIs, these bacteria cause many nosocomial infections such as sepsis, ulcers, gastroenteritis, and neonatal meningitis.
E. coli is resistant to β-lactam antibiotics due to the acquisition of plasmids encoding broad-spectrum β-lactamases (
7). The updated classification for β-lactamases includes group 1 cephalosporinases; group 2 broad-spectrum, inhibitor-resistant, and extended-spectrum β-lactamases, and serine carbapenemases; and group 3 metallo-β-lactamases (
8). Extended-spectrum β-lactamases (ESBLs) have particular importance in antimicrobial therapy and have the ability to hydrolyze the oxyimino-β-lactams such as cefotaxime, ceftazidime, ceftriaxone, or cefepime (
9). To date, more than 350 different natural ESBL variants are known classified into nine distinct families that the main ones are the TEM and SHV groups and CTX-M derivatives; in addition, IMP gene is also found in ESBL classes (
10). ESBLs are often reported in
E. coli and
Klebsiella spp., but are also detected in other Enterobacteriaceae (
11). In addition, ESBLs exhibit co-resistance to many other classes of antibiotics, resulting in the limitation of the therapeutic options (
9). Hence, bacteria producing broad-spectrum β-lactamases such as
E. coli are clinically important since they confer a broad spectrum of drug resistance patterns and increase mortality rate, especially in patients admitted to intensive care units (
12,
13). The prevalence of ESBL-producing
E. coli increased from 33.7% in 2005 to 60% in 2009 (
14). In the study by Boisen, out of 224
E. coli isolated strains, 116 samples (47.1%) were resistant to ceftazidime and 96 (39.2%) to cefoxitin, of which 109 strains were ESBL-positive. Also, TEM, CTX-M, and SHV genes were positive in 87.1%, 68.8%, and 70.6% of the isolates, respectively (
15). Soltan Dallal et al. in a study from Tehran, Iran showed that of the 200 isolated
E. coli, 128 strains were ESBL- producing, 99 of which harbored the CTX-M gene, and seven (5.5%) carriers the SHV gene (
16). In the study by Shahcheraghi et al. 93.6% of the strains produced ESBL enzymes inducing resistant against piperacillin, while resistance to piperacillin-tazobactam was observed in 26.6% of the patients (
17). In the study by Haghighat Panah et al. the results of susceptibility to antibiotics in different strains showed that the highest rate of resistance was to amoxicillin and all isolates were susceptible to imipenem, and the TEM gene detected in 32.5% of the strains had a direct relationship with resistance to antibiotics (
18).
Since resistance to antibiotics is increasing worldwide, especially in the developing countries, therefore, further studies are needed to determine the prevalence of resistance to antibiotics in E. coli and the necessity of using appropriate tools for infection control and optimal therapeutic strategies to reduce the prevalence of such bacteria. Some antibiotics such as ceftriaxone, imipenem, and piperacillin did not promote the colonization of ESBL-positive strains thus far and therefore, they are commonly administered to treat UTI. Hence, these antibiotics were evaluated in the present study.